Omeros Corporation
NASDAQ:OMERBiotechnology
+$0.43 today
- Market cap
- $1.01B
- Beta
- 2.53
- P/E (TTM)
- 8.4
- EPS (TTM)
- $1.20
Volume 5.34M
Average 1.55M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Omeros Corporation
NASDAQ:OMER
Intrinsic Alpha fair value
Locked
Current Price
$13.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Xencor, Inc. NASDAQ:XNCR | $2.78B | $37.09 | Not rated | -5.5 | +115.36% |
Arcus Biosciences, Inc. NYSE:RCUS | $2.51B | $17.43 | Not rated | -8.2 | -18.82% |
Biohaven Ltd. NYSE:BHVN | $2.09B | $13.82 | Not rated | -3.1 | +40.11% |
AnaptysBio, Inc. NASDAQ:ANAB | $1.38B | $46.25 | Overvalued | -59.7 | +84.88% |
Nektar Therapeutics NASDAQ:NKTR | $1.07B | $37.27 | Not rated | -9.3 | -39.31% |
Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | $897.52M | $10.64 | Not rated | -24.1 | +11.88% |
Cullinan Therapeutics, Inc. NASDAQ:CGEM | $667.39M | $10.28 | Not rated | -4.0 | +8.61% |
Compugen Ltd. NASDAQ:CGEN | $198.92M | $2.10 | Undervalued | 5.4 | +24.69% |
MacroGenics, Inc. NASDAQ:MGNX | $140.14M | $2.20 | Not rated | -3.6 | +33.12% |
Mereo BioPharma Group plc NASDAQ:MREO | $49.10M | $0.31 | Not rated | -1.4 | -82.42% |
Continue the stock analysis
Jump to another research area for this company.